The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | DOACs versus LMWH in patients with liver metastases & cancer-associated thrombosis
Jowan Al-Nusair, MD, Marshall University, Huntington, WV, discusses the findings of a retrospective multi-center real-world analysis comparing direct oral anticoagulants (DOACs) with low-molecular-weight heparin (LMWH) in patients with liver metastases and cancer-associated thrombosis. Dr Al-Nusair notes that DOACs may be favored over LMWH in this population, although anticoagulation should be individualized based on each patient’s bleeding risk and cancer burden. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
